SITC 2026: Next-Gen Immunotherapy Targets Resistance and Brain Cancers

MILWAUKEE, WI – October 29, 2026 — The Society for Immunotherapy of Cancer (SITC) has officially drawn the curtain back on its highly anticipated late-breaking abstract lineup for the 2026 Annual Meeting. Scheduled for November 4 through 8 in Phoenix, Arizona, and virtually, the 41st iteration of this premier oncology gathering received nearly 1,200 abstract submissions. Among these, a select group of late-breaking presentations stands out, spotlighting interventional clinical trial data that promises to reshape the commercial and clinical landscape of cancer care.

As an observer of the macroeconomic and technological forces driving biotech transformation, the data emerging from SITC this year signals a definitive pivot. We are moving past the era of broad-spectrum checkpoint inhibitors and entering a highly engineered, strategically targeted phase of oncology. The focus is no longer just on initiating an immune response, but on sustaining it, directing it past biological barriers, and doing so without bankrupting the patient's physical reserves or the healthcare system's financial resources.

Targeting Immunotherapy Resistance: The Battle Against PD-(L)1 Failure

The economic and clinical bottleneck of modern oncology is PD-1 resistance. Once hailed as a universal cure-all, immune checkpoint inhibitors have created a new demographic of patients: those whose tumors have evolved to outsmart standard therapies. The late-breaking abstracts selected for this year's press briefing highlight a multi-pronged attack on this exact demographic.

Leading the charge in biologics is cesalatamig (formerly AI-081), a differentiated PD-1/VEGF bispecific antibody developed by OncoC4 Inc. Kai He from the University of Texas Mays Cancer Center at San Antonio will present Phase 1/2 data on this novel agent. Cesalatamig is engineered with a high affinity for PD-1 and a significantly higher affinity for VEGF compared to legacy bevacizumab-based inhibitors, alongside critical Fc-silencing modifications. This design aims to simultaneously starve the tumor of its blood supply while uncloaking it to the immune system, all without depleting vital effector T cells. Having recently secured U.S. FDA Fast Track Designation for non-small cell lung cancer (NSCLC) patients who progressed on prior immunotherapy, this presentation will be closely watched by industry analysts eager to see if dual inhibition can break the resistance paradigm.

In the cellular therapy space, Rodabe Amaria from The University of Texas MD Anderson Cancer Center will present pooled safety and updated efficacy data on OBX-115. Sponsored by Obsidian Therapeutics, OBX-115 is a novel tumor-infiltrating lymphocyte (TIL) therapy designed for ICI-resistant advanced melanoma. Prior interim data demonstrated a striking 67% objective response rate in heavily pretreated patients. Crucially, this protocol utilizes minimally invasive tumor tissue procurement and a low-dose lymphodepletion regimen, addressing the logistical hurdles that have historically limited TIL therapy adoption.

Adding to the cellular arsenal, Sanghyun Kim from the National Cancer Institute will present an interim report on a Phase II clinical trial using the adoptive transfer of T cells engineered with mutant p53-specific TCRs. Targeting metastatic solid epithelial cancers, this approach moves beyond broad checkpoint blockade to exploit the specific genetic mutations driving cancer growth, offering a highly personalized intervention for treatment-resistant solid tumors.

Re-Engineering the Cytokine Arsenal: Safer, Smarter Immune Activation

Historically, immunotherapy has carried significant baggage in the form of severe toxicity. High-dose Interleukin-2 (IL-2), while curative for a small subset of patients, is burdened by extreme side effects like vascular leak syndrome, often requiring intensive care unit admission. The strategic innovation on display at SITC 2026 is the removal of this toxicity while preserving, or even enhancing, the therapeutic efficacy.

Obsidian's OBX-115 achieves this by armoring cells with pharmacologically regulatable membrane-bound IL15 (mbIL15), completely eliminating the need for systemic IL-2. This IL-2-free regimen is a game-changer for hospital economics. By mitigating severe adverse events and eliminating the need for ICU monitoring, this technology represents a strategic pivot toward outpatient-enabled cell therapy, drastically altering the Total Cost of Care (TCOC) for payers and providers.

Similarly, Werewolf Therapeutics is attacking the cytokine problem with WTX-124, a conditionally activated IL-2 INDUKINE molecule. Justin Moser from the HonorHealth Research Institute will present Phase 1/1b data on this prodrug, which is engineered to activate only within the tumor microenvironment. Previous interim data demonstrated unconfirmed partial responses and a manageable safety profile without severe IL-2-mediated toxicities. The financial backdrop is equally compelling; recent regulatory filings reveal the sponsor's strategic corporate restructuring and the issuance of contingent value rights tied to WTX-124's commercialization, illustrating the high financial stakes of solving the IL-2 toxicity puzzle.

In a fascinating and cost-effective pivot on existing medical technology, Ian Garbarine from The Ohio State University Comprehensive Cancer Center will present Phase 1b trial data on the intratumoral administration of the seasonal influenza vaccine in patients with melanoma. Clinical researchers suggest that repurposing widely available, approved vaccines to stimulate a localized immune response could offer a highly accessible, low-toxicity method to turn cold tumors hot, presenting a disruptive challenge to high-cost proprietary adjuvants.

Breaking the Blood-Brain Barrier: New Frontiers in CNS Malignancies

Brain tumors remain one of the most stubborn frontiers in oncology, historically impervious to the immunotherapy revolution due to the blood-brain barrier and a highly immunosuppressive microenvironment. This year's SITC lineup features a dedicated, multi-modal assault on central nervous system malignancies.

Kevin Reynolds of the Stanford Cancer Institute will share critical insights into why engineered T cells fail in the brain, presenting data on how adaptive anti-CAR immunity compromises the durability of GD2-CAR T cell therapy in diffuse midline glioma. Because this pediatric cancer is largely inoperable and devastatingly aggressive, understanding this failure mechanism is the essential first step toward engineering next-generation CARs that can persist and function within the central nervous system.

Meanwhile, Patrick Grogan from the Moffitt Cancer Center will present survival benefit data associated with adoptive immunotherapy using effector T lymphocytes generated following cancer neoantigen vaccination in patients with unmethylated Glioblastoma Multiforme (GBM). GBM is notoriously resistant to standard treatments, and utilizing a patient's own neoantigens to prime T cells represents a highly targeted, bespoke approach to a universally fatal disease.

Taking a viral approach to the same problem, Hong Jiang of MD Anderson Cancer Center will reveal how oncolytic adenoviruses can induce tertiary lymphoid structures in brain tumors. By essentially building an immune outpost directly within the brain tumor, this viral therapy aims to promote durable antitumor immunity, bridging the gap between innate and adaptive immune responses in a historically restricted anatomical space.

The Strategic Horizon of Oncology Investment

The true commercial and clinical impact of these therapies remains shielded by SITC's strict embargo policies, with detailed trial results tightly held until the presentations in Phoenix. However, a virtual press briefing scheduled for November 4 will offer early glimpses into these top advances, allowing participating members of the media to question presenters on patient survival endpoints and toxicity profiles.

The convergence of Fast Track Designations across these modalities—from WTX-124 to OBX-115 and cesalatamig—highlights a clear regulatory appetite for therapies that address refractory populations and mitigate severe toxicities. As healthcare systems globally grapple with the soaring costs of intensive cancer care, innovations that offer IL-2-free regimens, outpatient feasibility, or off-the-shelf viral components are not just clinical breakthroughs; they are economic imperatives. The data unveiled at the 41st Annual Meeting will undoubtedly set the tone for oncology investments and clinical trial designs heading into the late 2020s, proving that the future of cancer treatment lies in precision engineering and strategic, localized immune modulation.